3 results about "Hypovolemia" patented technology

A method for collecting blood components from a subject using an automated blood collection system includes: separating plasma from whole blood received from the subject; initiating an alert when the predicted cumulative volume loss is greater than a configured removal level, the predicted cumulative volume loss depending on a cumulative volume comprising the separated plasma volume, the configured removal level defined by a pre-selected maximum value or a low blood volume level for the subject; and in response to feedback and alerts from an operator of the automated blood collection system, ending the process of collection, continuing collection, or initiating separation of platelets and erythrocytes.

The application provides a kind of pancreatitis patient fluid intake and output quantity comprehensive monitoring method, comprising the following steps: obtaining the fluid intake and output quantity data and blood gas analysis data of pancreatitis patient and other data;Set liquid demand quantity prediction model, according to the preprocessed multidimensional monitoring data set and liquid demand quantity prediction model, liquid demand quantity prediction is carried out;Set the time series risk early warning model based on LSTM, according to the preprocessed multidimensional monitoring data set and liquid demand quantity prediction model, risk prediction is carried out;According to the prediction result of risk prediction, generate liquid management early warning information and fluid replacement scheme adjustment suggestion;According to the prediction result of liquid demand quantity prediction, the risk probability of future occurrence of liquid overload, hypovolemia or abdominal cavity high pressure syndrome of patient is predicted.The application can realize the intelligent prediction of individualized liquid demand quantity and the early dynamic early warning of complication risk, generate liquid management suggestion, to assist clinical precise and predictive liquid treatment.

The invention relates to methods for improving treatment outcomes in patients undergoing ultrafiltration. Ultrafiltration during hemodialysis or fluid removal can induce sympathetic nervous system activation, hypovolemia, catecholamine surge, and widespread microvascular ischemia, leading to cardiac stunning, dialysis intolerance, and organ injury. Disclosed herein are methods of administering a therapeutically effective amount of one or more receptor agonists of the renin-angiotensin system (RAS), including angiotensin II, angiotensin III, angiotensin IV, angiotensin 1-7, and / or prorenin receptor (PRR) agonists, to maintain capillary perfusion and prevent ischemia. The methods reduce risk or incidence of catecholamine surge, intradialytic hypotension, cardiac dysfunction, and muscle cramps, and also prevent or minimize systemic ischemic injury to the brain, heart, kidneys, liver, and skeletal muscle. By preserving systemic microvascular blood flow, the disclosed methods mitigate or prevent dialysis-associated heart disease as well as neurocognitive impairment, including white matter injury, memory decline, and executive dysfunction. These approaches enable improved hemodynamic stability, achieving ultrafiltration targets without the need to adjust treatment goals, reducing the necessity for fluid bolus administration, aiding in reaching dry weight, achievement of dry weight goals, minimizing the occurrence and severity of skeletal muscle cramps, and reduced long-term cardiovascular and neurological complications in patients receiving ultrafiltration therapy.